Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
08/27/2003 | CN1119313C Inhibition of matrix metallo proteases by 2-(omega-aroylalkyc)-4-biaryl-oxobutyric acids |
08/27/2003 | CN1119151C Preparation of medicine for restoring the normal transmitting function of nerve |
08/27/2003 | CN1119148C Use of alpha 1L agonists in treatment of in continence |
08/26/2003 | US6610906 Nucleotide sequences for gene regulation and methods of use thereof |
08/26/2003 | US6610847 Tyrosine kinase inhibitors; immunosuppressants |
08/26/2003 | US6610820 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
08/26/2003 | US6610745 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS |
08/26/2003 | US6610744 Methods of treatment with compounds having RARα receptor specific or selective activity |
08/26/2003 | US6610743 Bicyclic metabotropic glutamate receptor ligands |
08/26/2003 | US6610737 Non-psychotropic cannabinoids |
08/26/2003 | US6610734 Heterocyclic sulfonamide inhibitors of beta amyloid production |
08/26/2003 | US6610725 Fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
08/26/2003 | US6610723 Imidazole derivatives |
08/26/2003 | US6610717 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease |
08/26/2003 | US6610716 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
08/26/2003 | US6610712 Aryloxy piperidinyl derivatives for the treatment of depression |
08/26/2003 | US6610707 Heterocyclic compounds as inhibitors of rotomase enzymes |
08/26/2003 | US6610703 Administering long-chain N-alkyl derivative of deoxynojirimycin having from nine to about twenty carbon atoms in alkyl chain |
08/26/2003 | US6610700 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example |
08/26/2003 | US6610697 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
08/26/2003 | US6610696 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) |
08/26/2003 | US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease |
08/26/2003 | US6610690 Administering optically pure (S,S) enantiomer of reboxetine |
08/26/2003 | US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer |
08/26/2003 | US6610685 Fused indole derivatives |
08/26/2003 | US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
08/26/2003 | US6610681 Neurotherapeutic clavulanate composition and method |
08/26/2003 | US6610678 Corticotropin-releasing factor antagonists; treating endocrine, psychiatric or neurologic disorders |
08/26/2003 | US6610665 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives |
08/26/2003 | US6610658 Modulators of μ-amyloid peptide aggregation |
08/26/2003 | US6610540 Low oxygen culturing of central nervous system progenitor cells |
08/26/2003 | US6610324 Analgesics; rheumatic diseases; muscular disorders; sleep disorders |
08/26/2003 | US6610271 System and method for intranasal administration of lorazepam |
08/26/2003 | CA2092211C Imidazole compounds, their preparation and use |
08/21/2003 | WO2003068970A1 Sodium-independent transporter carrying acidic amino acid and its gene |
08/21/2003 | WO2003068959A1 Novel screening method |
08/21/2003 | WO2003068937A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
08/21/2003 | WO2003068812A2 Immune-modulating peptide made of s. aureus enterotoxin b |
08/21/2003 | WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia |
08/21/2003 | WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
08/21/2003 | WO2003068776A1 [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
08/21/2003 | WO2003068773A1 Pyrazolopyridine derivatives |
08/21/2003 | WO2003068772A1 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
08/21/2003 | WO2003068771A1 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
08/21/2003 | WO2003068769A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
08/21/2003 | WO2003068768A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity |
08/21/2003 | WO2003068760A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
08/21/2003 | WO2003068759A1 Piperazine derivatives as anti-inflammatory agents |
08/21/2003 | WO2003068755A1 Novel tricycloimidazoline derivatives, method for production and use thereof as medicaments |
08/21/2003 | WO2003068754A1 Therapeutic substituted indazole derivatives |
08/21/2003 | WO2003068752A1 Benzenesulfonamide derivatives as antipsychotic agents |
08/21/2003 | WO2003068751A1 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
08/21/2003 | WO2003068750A1 Jnk inhibitor |
08/21/2003 | WO2003068749A1 Vanilloid receptor modulators |
08/21/2003 | WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors |
08/21/2003 | WO2003068746A1 Aryl ureas as kinase inhibitors |
08/21/2003 | WO2003068744A1 Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
08/21/2003 | WO2003068743A1 Chemical compounds |
08/21/2003 | WO2003068740A1 Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands |
08/21/2003 | WO2003068734A1 Carbamide esters for treating pain |
08/21/2003 | WO2003068732A2 Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
08/21/2003 | WO2003068731A1 Beta-amino ketones for the treatment of pain |
08/21/2003 | WO2003068251A1 Herbal formulation for treating attention defienciency disorder (add/adht) and process for preparation |
08/21/2003 | WO2003068238A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
08/21/2003 | WO2003068236A1 Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors |
08/21/2003 | WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors |
08/21/2003 | WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases |
08/21/2003 | WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors |
08/21/2003 | WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase |
08/21/2003 | WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity |
08/21/2003 | WO2003068226A1 2-oxazolamines and their use as 5-ht2b receptor antagonists |
08/21/2003 | WO2003068220A1 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders |
08/21/2003 | WO2003068218A1 Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
08/21/2003 | WO2003068215A1 Drugs for mitochondrial diseases |
08/21/2003 | WO2003068211A1 Methods of treating attention deficit/hyperactivity disorder (adhd) |
08/21/2003 | WO2003068210A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
08/21/2003 | WO2003068207A2 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
08/21/2003 | WO2003068199A1 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta |
08/21/2003 | WO2003068197A1 Method for systemic drug delivery through the nail |
08/21/2003 | WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders |
08/21/2003 | WO2003068169A2 Stabilized synthetic immunogen delivery system |
08/21/2003 | WO2003068168A2 Helical peptidomimetics and use b-amyloid-associated diseases |
08/21/2003 | WO2003068166A2 Treatment of ophthalmic disorders using urea and urea derivatives |
08/21/2003 | WO2003068148A2 Treatment of sleep disorders using sleep target modulators |
08/21/2003 | WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same |
08/21/2003 | WO2003060142A9 Compositions and methods for controlled release |
08/21/2003 | WO2003055913A3 Secreted protein |
08/21/2003 | WO2003054014A3 Apolipoprotein biopolymer markers predictive of alzheimers disease |
08/21/2003 | WO2003037890A3 Piperidines |
08/21/2003 | WO2003037254A3 Methods and compositions for the treatment and diagnosis of pain disorders using 46566 |
08/21/2003 | WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
08/21/2003 | WO2003024935A3 Substituted pyrazolyl compounds for the treatment of inflammation |
08/21/2003 | WO2003024474A3 Anti-inflammatory agent |
08/21/2003 | WO2003024471A3 Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
08/21/2003 | WO2003020217A3 Novel pyrazole analogs acting on cannabinoid receptors |
08/21/2003 | WO2003011220A3 Animal model for fatty acid amide-related neurobehaviors |
08/21/2003 | WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
08/21/2003 | WO2002089779A3 Combined preparation for the prophylaxis and/or therapy of nerve cell and/or glia cell damage using a novel method of treatment |
08/21/2003 | WO2002088664A3 Control of compactability through crystallization |
08/21/2003 | WO2002083182A3 The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification |